NOTVQ Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-2.480.0% YoY
Profit margin-17.1%HEALTHCARE
Market cap$453540Micro cap

Valuation

Forward P/E
PEG ratio
P/B
0.01
P/S (TTM)
0.00
EV/EBITDA
68.69

Profitability & growth

ROE (TTM)
-74.1%
Operating margin
-16.0%
Revenue growth YoY
-5.4%
Dividend yield
Beta
3.77
Last earnings
Mar 31, 2026 · Estimate $-0.64 · Reported $-0.94
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Inotiv, Inc.

Inotiv, Inc. (NOTVQ) is a leading preclinical contract research organization specializing in drug development and safety assessment services for the biotech and pharmaceutical industries. The company offers a comprehensive range of solutions, including nonclinical imaging, pharmacology, and toxicology, to support the development of new therapeutics. Driven by innovation and a commitment to scientific excellence, Inotiv leverages advanced technologies and a highly skilled workforce to deliver valuable insights and data that facilitate the drug discovery process. With a growing portfolio of…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
2701 KENT AVENUE, WEST LAFAYETTE, IN
Fiscal year end
September
Latest quarter
Mar 31, 2026
Market cap$453540
Shares outstanding$34.9M
52W high$0.33
52W low$0.01

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer